#好币推荐#

Recently, the acquisition intention of Navigating Medicine Biotechnology (HK) towards Conflux (CFX) has attracted high market attention!

NaviHealth signed a memorandum of understanding on June 30, 2025, intending to acquire Conflux blockchain assets through cash, shares, or convertible bonds. The target company will be registered in the Cayman Islands, and the transaction will be valid for 12 months, during which the seller shall not negotiate with other parties.

The acquisition motivation is clearly for business diversification, entering the blockchain field to seek new profit growth points, and both founders of Conflux serve as executive directors of Linghang Pharmaceuticals, suggesting that resource integration may deepen.

Regarding the fundamentals of CFX coin, I see that it is the native token of Conflux Network, referred to as "China's Ethereum".

As a Cfx supported by Chinese policy and regarded as the "only compliant public chain," the Hong Kong concept, and the Hong Kong-listed company crossing over into blockchain, it attracts the attention of traditional capital, which may boost market activity.

Core driving variables for the future outlook:
1. Cfx mainnet upgrade is imminent (cross-chain capability, transaction speed)
2. Obtaining compliance licenses in China and globally (such as Hong Kong virtual asset licenses)
3. Overall liquidity in the cryptocurrency market (July Federal Reserve interest rate cut expectations)

Strategy Recommendations:
Buy on dips, hold for the long term, medium to long-term target $1.0